Sydney Jennings

Articles

Early Hypertensive Screening in Patients with Obesity: Expert Perspective

January 14, 2025

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

January 14, 2025

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

CRC Screening Expansion Strains Community Health Centers: Daily Dose

January 14, 2025

Your daily dose of the clinical news you may have missed.

Phase 1b Trial of Oligomer-Targeting Agent PMN310 for Alzheimer Disease Gets Underway

January 13, 2025

The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.

Women Show Higher Genetic Predisposition to PTSD: Daily Dose

January 13, 2025

Your daily dose of the clinical news you may have missed.

Managing Hypertension in Patients with Obesity: Clinician Strategies for Long-Term Care

January 10, 2025

Caissa Troutman, MD, an obesity medicine and family medicine physician, emphasizes early treatment of obesity, along with HTN management, can improve patient outcomes.

Orexo Announces Positive Topline Data for Nasal Epinephrine Powder OX640 in People with Allergic Rhinitis

January 10, 2025

Treatments with the investigational rescue medication achieved clinically effective epinephrine levels faster than intramuscular injection.

Viking Therapeutics Launches Phase 2 Trial for Oral VK2735 in Patients with Obesity

January 09, 2025

The trial builds on results from a previous phase 1 study that showed dose-dependent weight loss and favorable tolerability for VK2735 in people with obesity.

Mobile App Shows Promise for Hypertension Management: Daily Dose

January 09, 2025

Your daily dose of the clinical news you may have missed.

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

January 08, 2025

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.